Industry Research Reports

• Description
• Table of Contents
• Table of Figures
• PDF Download

Pelvic congestion syndrome is a condition that causes pain in the pelvic region. This pain occurs mostly due to problems in the veins near the pelvic area. Pelvic congestion syndrome is a common gynecological condition in women that leads to often severe chronic pelvic pain. The causes of pelvic congestion syndrome generally involves pelvic inflammatory disease, endometriosis, pelvic varicosities and other conditions. Mostly in hospitals, pelvic congestion syndrome diagnosis is generally performed by venography. Prior to venogram, a pelvic ultrasound or other imaging study is performed to check any abnormalities.

Market Analysis and Insights: Global and United States Pelvic Congestion Syndrome Treatment Market
This report focuses on global and United States Pelvic Congestion Syndrome Treatment market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Pelvic Congestion Syndrome Treatment market size is estimated to be worth US$  million in 2022 and is forecast to a readjusted size of US$  million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) accounting for % of the Pelvic Congestion Syndrome Treatment global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Primary Pelvic Congestion Syndrome was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

In United States the Pelvic Congestion Syndrome Treatment market size is expected to grow from US$  million in 2021 to US$  million by 2028, at a CAGR of % during the forecast period  2022-2028.

Global Pelvic Congestion Syndrome Treatment Scope and Market Size
Pelvic Congestion Syndrome Treatment market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Pelvic Congestion Syndrome Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Pelvic Congestion Syndrome Treatment market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
    NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)
    Dihydroergotamine
    Progestins
    Others

Segment by Application
    Primary Pelvic Congestion Syndrome
    Secondary Pelvic Congestion Syndrome

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
        Colombia
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    Sanofi
    TOLMAR
    Actiza Pharmaceutical
    Pfizer
    Debiopharm Group
    AbbVie
    AstraZeneca
    Novartis
    Indivior
    Johnson and Johnson
    Fresenius Kabi
    TerSera Therapeutics
    Takeda
    Ferring

 1 Study Coverage
    1.1 Pelvic Congestion Syndrome Treatment Product Introduction
    1.2 Global Pelvic Congestion Syndrome Treatment Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Pelvic Congestion Syndrome Treatment Sales in US$ Million for the Year 2017-2028
        1.2.2 Global Pelvic Congestion Syndrome Treatment Sales in Volume for the Year 2017-2028
    1.3 United States Pelvic Congestion Syndrome Treatment Outlook 2017 VS 2022 VS 2028
        1.3.1 United States Pelvic Congestion Syndrome Treatment Sales in US$ Million for the Year 2017-2028
        1.3.2 United States Pelvic Congestion Syndrome Treatment Sales in Volume for the Year 2017-2028
    1.4 Pelvic Congestion Syndrome Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.4.1 The Market Share of United States Pelvic Congestion Syndrome Treatment in Global, 2017 VS 2022 VS 2028
        1.4.2 The Growth Rate of Pelvic Congestion Syndrome Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.5 Pelvic Congestion Syndrome Treatment Market Dynamics
        1.5.1 Pelvic Congestion Syndrome Treatment Industry Trends
        1.5.2 Pelvic Congestion Syndrome Treatment Market Drivers
        1.5.3 Pelvic Congestion Syndrome Treatment Market Challenges
        1.5.4 Pelvic Congestion Syndrome Treatment Market Restraints
    1.6 Study Objectives
    1.7 Years Considered

 2 Market by Type
    2.1 Pelvic Congestion Syndrome Treatment Market Segment by Type
        2.1.1 NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)
        2.1.2 Dihydroergotamine
        2.1.3 Progestins
        2.1.4 Others
    2.2 Global Pelvic Congestion Syndrome Treatment Market Size by Type
        2.2.1 Global Pelvic Congestion Syndrome Treatment Sales in Value, by Type (2017, 2022 & 2028)
        2.2.2 Global Pelvic Congestion Syndrome Treatment Sales in Volume, by Type (2017, 2022 & 2028)
        2.2.3 Global Pelvic Congestion Syndrome Treatment Average Selling Price (ASP) by Type (2017, 2022 & 2028)
    2.3 United States Pelvic Congestion Syndrome Treatment Market Size by Type
        2.3.1 United States Pelvic Congestion Syndrome Treatment Sales in Value, by Type (2017, 2022 & 2028)
        2.3.2 United States Pelvic Congestion Syndrome Treatment Sales in Volume, by Type (2017, 2022 & 2028)
        2.3.3 United States Pelvic Congestion Syndrome Treatment Average Selling Price (ASP) by Type (2017, 2022 & 2028)

 3 Market by Application
    3.1 Pelvic Congestion Syndrome Treatment Market Segment by Application
        3.1.1 Primary Pelvic Congestion Syndrome
        3.1.2 Secondary Pelvic Congestion Syndrome
    3.2 Global Pelvic Congestion Syndrome Treatment Market Size by Application
        3.2.1 Global Pelvic Congestion Syndrome Treatment Sales in Value, by Application (2017, 2022 & 2028)
        3.2.2 Global Pelvic Congestion Syndrome Treatment Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 Global Pelvic Congestion Syndrome Treatment Average Selling Price (ASP) by Application (2017, 2022 & 2028)
    3.3 United States Pelvic Congestion Syndrome Treatment Market Size by Application
        3.3.1 United States Pelvic Congestion Syndrome Treatment Sales in Value, by Application (2017, 2022 & 2028)
        3.3.2 United States Pelvic Congestion Syndrome Treatment Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 United States Pelvic Congestion Syndrome Treatment Average Selling Price (ASP) by Application (2017, 2022 & 2028)

 4 Global Pelvic Congestion Syndrome Treatment Competitor Landscape by Company
    4.1 Global Pelvic Congestion Syndrome Treatment Market Size by Company
        4.1.1 Top Global Pelvic Congestion Syndrome Treatment Manufacturers Ranked by Revenue (2021)
        4.1.2 Global Pelvic Congestion Syndrome Treatment Revenue by Manufacturer (2017-2022)
        4.1.3 Global Pelvic Congestion Syndrome Treatment Sales by Manufacturer (2017-2022)
        4.1.4 Global Pelvic Congestion Syndrome Treatment Price by Manufacturer (2017-2022)
    4.2 Global Pelvic Congestion Syndrome Treatment Concentration Ratio (CR)
        4.2.1 Pelvic Congestion Syndrome Treatment Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Pelvic Congestion Syndrome Treatment in 2021
        4.2.3 Global Pelvic Congestion Syndrome Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Pelvic Congestion Syndrome Treatment Manufacturing Base Distribution, Product Type
        4.3.1 Global Pelvic Congestion Syndrome Treatment Manufacturers, Headquarters and Distribution of Producing Region
        4.3.2 Manufacturers Pelvic Congestion Syndrome Treatment Product Type
        4.3.3 Date of International Manufacturers Enter into Pelvic Congestion Syndrome Treatment Market
    4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
    4.5 United States Pelvic Congestion Syndrome Treatment Market Size by Company
        4.5.1 Top Pelvic Congestion Syndrome Treatment Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Pelvic Congestion Syndrome Treatment Revenue by Players (2020, 2021 & 2022)
        4.5.3 United States Pelvic Congestion Syndrome Treatment Sales by Players (2020, 2021 & 2022)

 5 Global Pelvic Congestion Syndrome Treatment Market Size by Region
    5.1 Global Pelvic Congestion Syndrome Treatment Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Pelvic Congestion Syndrome Treatment Market Size in Volume by Region (2017-2028)
        5.2.1 Global Pelvic Congestion Syndrome Treatment Sales in Volume by Region: 2017-2022
        5.2.2 Global Pelvic Congestion Syndrome Treatment Sales in Volume Forecast by Region (2023-2028)
    5.3 Global Pelvic Congestion Syndrome Treatment Market Size in Value by Region (2017-2028)
        5.3.1 Global Pelvic Congestion Syndrome Treatment Sales in Value by Region: 2017-2022
        5.3.2 Global Pelvic Congestion Syndrome Treatment Sales in Value by Region: 2023-2028

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Pelvic Congestion Syndrome Treatment Market Size YoY Growth 2017-2028
        6.1.2 North America Pelvic Congestion Syndrome Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 United States
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Pelvic Congestion Syndrome Treatment Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Pelvic Congestion Syndrome Treatment Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 China Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
    6.3 Europe
        6.3.1 Europe Pelvic Congestion Syndrome Treatment Market Size YoY Growth 2017-2028
        6.3.2 Europe Pelvic Congestion Syndrome Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Pelvic Congestion Syndrome Treatment Market Size YoY Growth 2017-2028
        6.4.2 Latin America Pelvic Congestion Syndrome Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
        6.4.6 Colombia
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Pelvic Congestion Syndrome Treatment Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Pelvic Congestion Syndrome Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 Sanofi
        7.1.1 Sanofi Corporation Information
        7.1.2 Sanofi Description and Business Overview
        7.1.3 Sanofi Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.1.4 Sanofi Pelvic Congestion Syndrome Treatment Products Offered
        7.1.5 Sanofi Recent Development
    7.2 TOLMAR
        7.2.1 TOLMAR Corporation Information
        7.2.2 TOLMAR Description and Business Overview
        7.2.3 TOLMAR Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.2.4 TOLMAR Pelvic Congestion Syndrome Treatment Products Offered
        7.2.5 TOLMAR Recent Development
    7.3 Actiza Pharmaceutical
        7.3.1 Actiza Pharmaceutical Corporation Information
        7.3.2 Actiza Pharmaceutical Description and Business Overview
        7.3.3 Actiza Pharmaceutical Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.3.4 Actiza Pharmaceutical Pelvic Congestion Syndrome Treatment Products Offered
        7.3.5 Actiza Pharmaceutical Recent Development
    7.4 Pfizer
        7.4.1 Pfizer Corporation Information
        7.4.2 Pfizer Description and Business Overview
        7.4.3 Pfizer Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.4.4 Pfizer Pelvic Congestion Syndrome Treatment Products Offered
        7.4.5 Pfizer Recent Development
    7.5 Debiopharm Group
        7.5.1 Debiopharm Group Corporation Information
        7.5.2 Debiopharm Group Description and Business Overview
        7.5.3 Debiopharm Group Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.5.4 Debiopharm Group Pelvic Congestion Syndrome Treatment Products Offered
        7.5.5 Debiopharm Group Recent Development
    7.6 AbbVie
        7.6.1 AbbVie Corporation Information
        7.6.2 AbbVie Description and Business Overview
        7.6.3 AbbVie Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.6.4 AbbVie Pelvic Congestion Syndrome Treatment Products Offered
        7.6.5 AbbVie Recent Development
    7.7 AstraZeneca
        7.7.1 AstraZeneca Corporation Information
        7.7.2 AstraZeneca Description and Business Overview
        7.7.3 AstraZeneca Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.7.4 AstraZeneca Pelvic Congestion Syndrome Treatment Products Offered
        7.7.5 AstraZeneca Recent Development
    7.8 Novartis
        7.8.1 Novartis Corporation Information
        7.8.2 Novartis Description and Business Overview
        7.8.3 Novartis Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.8.4 Novartis Pelvic Congestion Syndrome Treatment Products Offered
        7.8.5 Novartis Recent Development
    7.9 Indivior
        7.9.1 Indivior Corporation Information
        7.9.2 Indivior Description and Business Overview
        7.9.3 Indivior Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.9.4 Indivior Pelvic Congestion Syndrome Treatment Products Offered
        7.9.5 Indivior Recent Development
    7.10 Johnson and Johnson
        7.10.1 Johnson and Johnson Corporation Information
        7.10.2 Johnson and Johnson Description and Business Overview
        7.10.3 Johnson and Johnson Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.10.4 Johnson and Johnson Pelvic Congestion Syndrome Treatment Products Offered
        7.10.5 Johnson and Johnson Recent Development
    7.11 Fresenius Kabi
        7.11.1 Fresenius Kabi Corporation Information
        7.11.2 Fresenius Kabi Description and Business Overview
        7.11.3 Fresenius Kabi Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.11.4 Fresenius Kabi Pelvic Congestion Syndrome Treatment Products Offered
        7.11.5 Fresenius Kabi Recent Development
    7.12 TerSera Therapeutics
        7.12.1 TerSera Therapeutics Corporation Information
        7.12.2 TerSera Therapeutics Description and Business Overview
        7.12.3 TerSera Therapeutics Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.12.4 TerSera Therapeutics Products Offered
        7.12.5 TerSera Therapeutics Recent Development
    7.13 Takeda
        7.13.1 Takeda Corporation Information
        7.13.2 Takeda Description and Business Overview
        7.13.3 Takeda Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.13.4 Takeda Products Offered
        7.13.5 Takeda Recent Development
    7.14 Ferring
        7.14.1 Ferring Corporation Information
        7.14.2 Ferring Description and Business Overview
        7.14.3 Ferring Pelvic Congestion Syndrome Treatment Sales, Revenue and Gross Margin (2017-2022)
        7.14.4 Ferring Products Offered
        7.14.5 Ferring Recent Development

 8 Industry Chain and Sales Channels Analysis
    8.1 Pelvic Congestion Syndrome Treatment Industry Chain Analysis
    8.2 Pelvic Congestion Syndrome Treatment Key Raw Materials
        8.2.1 Key Raw Materials
        8.2.2 Pelvic Congestion Syndrome Treatment Distributors
    8.3 Pelvic Congestion Syndrome Treatment Production Mode & Process
    8.4 Pelvic Congestion Syndrome Treatment Sales and Marketing
        8.4.1 Pelvic Congestion Syndrome Treatment Sales Channels
        8.4.2 Pelvic Congestion Syndrome Treatment Distributors
    8.5 Pelvic Congestion Syndrome Treatment Customers

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. Pelvic Congestion Syndrome Treatment CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Pelvic Congestion Syndrome Treatment Market Trends
    Table 3. Pelvic Congestion Syndrome Treatment Market Drivers
    Table 4. Pelvic Congestion Syndrome Treatment Market Challenges
    Table 5. Pelvic Congestion Syndrome Treatment Market Restraints
    Table 6. Global Pelvic Congestion Syndrome Treatment Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Pelvic Congestion Syndrome Treatment Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Pelvic Congestion Syndrome Treatment Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Pelvic Congestion Syndrome Treatment Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Pelvic Congestion Syndrome Treatment Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Pelvic Congestion Syndrome Treatment Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Pelvic Congestion Syndrome Treatment Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Pelvic Congestion Syndrome Treatment Sales by Manufacturer, (K Units), 2017-2022
    Table 14. Global Pelvic Congestion Syndrome Treatment Sales Share by Manufacturer, 2017-2022
    Table 15. Global Pelvic Congestion Syndrome Treatment Price by Manufacturer (2017-2022) & (US$/Unit)
    Table 16. Global Pelvic Congestion Syndrome Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Pelvic Congestion Syndrome Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pelvic Congestion Syndrome Treatment as of 2021)
    Table 18. Top Players of Pelvic Congestion Syndrome Treatment in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Pelvic Congestion Syndrome Treatment Product Type
    Table 20. Date of International Manufacturers Enter into Pelvic Congestion Syndrome Treatment Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Pelvic Congestion Syndrome Treatment Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Pelvic Congestion Syndrome Treatment Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Pelvic Congestion Syndrome Treatment Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Pelvic Congestion Syndrome Treatment Sales by Players, (K Units), 2020, 2021 & 2022
    Table 26. United States Pelvic Congestion Syndrome Treatment Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Pelvic Congestion Syndrome Treatment Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Pelvic Congestion Syndrome Treatment Sales in Volume by Region (2017-2022) & (K Units)
    Table 29. Global Pelvic Congestion Syndrome Treatment Sales in Volume Forecast by Region (2023-2028) & (K Units)
    Table 30. Global Pelvic Congestion Syndrome Treatment Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Pelvic Congestion Syndrome Treatment Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Pelvic Congestion Syndrome Treatment Sales in Volume by Country (2017-2028) & (K Units)
    Table 33. North America Pelvic Congestion Syndrome Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Pelvic Congestion Syndrome Treatment Sales in Volume by Region (2017-2028) & (K Units)
    Table 35. Asia Pacific Pelvic Congestion Syndrome Treatment Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Pelvic Congestion Syndrome Treatment Sales in Volume by Country (2017-2028) & (K Units)
    Table 37. Europe Pelvic Congestion Syndrome Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Pelvic Congestion Syndrome Treatment Sales in Volume by Country (2017-2028) & (K Units)
    Table 39. Latin Americaa Pelvic Congestion Syndrome Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Pelvic Congestion Syndrome Treatment Sales in Volume by Country (2017-2028) & (K Units)
    Table 41. Middle East and Africa Pelvic Congestion Syndrome Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Sanofi Corporation Information
    Table 43. Sanofi Description and Business Overview
    Table 44. Sanofi Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 45. Sanofi Pelvic Congestion Syndrome Treatment Product
    Table 46. Sanofi Recent Development
    Table 47. TOLMAR Corporation Information
    Table 48. TOLMAR Description and Business Overview
    Table 49. TOLMAR Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 50. TOLMAR Product
    Table 51. TOLMAR Recent Development
    Table 52. Actiza Pharmaceutical Corporation Information
    Table 53. Actiza Pharmaceutical Description and Business Overview
    Table 54. Actiza Pharmaceutical Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 55. Actiza Pharmaceutical Product
    Table 56. Actiza Pharmaceutical Recent Development
    Table 57. Pfizer Corporation Information
    Table 58. Pfizer Description and Business Overview
    Table 59. Pfizer Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 60. Pfizer Product
    Table 61. Pfizer Recent Development
    Table 62. Debiopharm Group Corporation Information
    Table 63. Debiopharm Group Description and Business Overview
    Table 64. Debiopharm Group Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 65. Debiopharm Group Product
    Table 66. Debiopharm Group Recent Development
    Table 67. AbbVie Corporation Information
    Table 68. AbbVie Description and Business Overview
    Table 69. AbbVie Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 70. AbbVie Product
    Table 71. AbbVie Recent Development
    Table 72. AstraZeneca Corporation Information
    Table 73. AstraZeneca Description and Business Overview
    Table 74. AstraZeneca Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 75. AstraZeneca Product
    Table 76. AstraZeneca Recent Development
    Table 77. Novartis Corporation Information
    Table 78. Novartis Description and Business Overview
    Table 79. Novartis Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 80. Novartis Product
    Table 81. Novartis Recent Development
    Table 82. Indivior Corporation Information
    Table 83. Indivior Description and Business Overview
    Table 84. Indivior Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 85. Indivior Product
    Table 86. Indivior Recent Development
    Table 87. Johnson and Johnson Corporation Information
    Table 88. Johnson and Johnson Description and Business Overview
    Table 89. Johnson and Johnson Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 90. Johnson and Johnson Product
    Table 91. Johnson and Johnson Recent Development
    Table 92. Fresenius Kabi Corporation Information
    Table 93. Fresenius Kabi Description and Business Overview
    Table 94. Fresenius Kabi Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 95. Fresenius Kabi Product
    Table 96. Fresenius Kabi Recent Development
    Table 97. TerSera Therapeutics Corporation Information
    Table 98. TerSera Therapeutics Description and Business Overview
    Table 99. TerSera Therapeutics Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 100. TerSera Therapeutics Product
    Table 101. TerSera Therapeutics Recent Development
    Table 102. Takeda Corporation Information
    Table 103. Takeda Description and Business Overview
    Table 104. Takeda Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 105. Takeda Product
    Table 106. Takeda Recent Development
    Table 107. Ferring Corporation Information
    Table 108. Ferring Description and Business Overview
    Table 109. Ferring Pelvic Congestion Syndrome Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 110. Ferring Product
    Table 111. Ferring Recent Development
    Table 112. Key Raw Materials Lists
    Table 113. Raw Materials Key Suppliers Lists
    Table 114. Pelvic Congestion Syndrome Treatment Customers List
    Table 115. Pelvic Congestion Syndrome Treatment Distributors List
    Table 116. Research Programs/Design for This Report
    Table 117. Key Data Information from Secondary Sources
    Table 118. Key Data Information from Primary Sources
List of Figures
    Figure 1. Pelvic Congestion Syndrome Treatment Product Picture
    Figure 2. Global Pelvic Congestion Syndrome Treatment Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Pelvic Congestion Syndrome Treatment Market Size 2017-2028 (US$ Million)
    Figure 4. Global Pelvic Congestion Syndrome Treatment Sales 2017-2028 (K Units)
    Figure 5. United States Pelvic Congestion Syndrome Treatment Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Pelvic Congestion Syndrome Treatment Market Size 2017-2028 (US$ Million)
    Figure 7. United States Pelvic Congestion Syndrome Treatment Sales 2017-2028 (K Units)
    Figure 8. United States Pelvic Congestion Syndrome Treatment Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Pelvic Congestion Syndrome Treatment Market Share in Global, in Volume (K Units) 2017-2028
    Figure 10. Pelvic Congestion Syndrome Treatment Report Years Considered
    Figure 11. Product Picture of NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)
    Figure 12. Product Picture of Dihydroergotamine
    Figure 13. Product Picture of Progestins
    Figure 14. Product Picture of Others
    Figure 15. Global Pelvic Congestion Syndrome Treatment Market Share by Type in 2022 & 2028
    Figure 16. Global Pelvic Congestion Syndrome Treatment Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 17. Global Pelvic Congestion Syndrome Treatment Sales Market Share in Value by Type (2017-2028)
    Figure 18. Global Pelvic Congestion Syndrome Treatment Sales by Type (2017-2028) & (K Units)
    Figure 19. Global Pelvic Congestion Syndrome Treatment Sales Market Share in Volume by Type (2017-2028)
    Figure 20. Global Pelvic Congestion Syndrome Treatment Price by Type (2017-2028) & (US$/Unit)
    Figure 21. United States Pelvic Congestion Syndrome Treatment Market Share by Type in 2022 & 2028
    Figure 22. United States Pelvic Congestion Syndrome Treatment Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 23. United States Pelvic Congestion Syndrome Treatment Sales Market Share in Value by Type (2017-2028)
    Figure 24. United States Pelvic Congestion Syndrome Treatment Sales by Type (2017-2028) & (K Units)
    Figure 25. United States Pelvic Congestion Syndrome Treatment Sales Market Share in Volume by Type (2017-2028)
    Figure 26. United States Pelvic Congestion Syndrome Treatment Price by Type (2017-2028) & (US$/Unit)
    Figure 27. Product Picture of Primary Pelvic Congestion Syndrome
    Figure 28. Product Picture of Secondary Pelvic Congestion Syndrome
    Figure 29. Global Pelvic Congestion Syndrome Treatment Market Share by Application in 2022 & 2028
    Figure 30. Global Pelvic Congestion Syndrome Treatment Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 31. Global Pelvic Congestion Syndrome Treatment Sales Market Share in Value by Application (2017-2028)
    Figure 32. Global Pelvic Congestion Syndrome Treatment Sales by Application (2017-2028) & (K Units)
    Figure 33. Global Pelvic Congestion Syndrome Treatment Sales Market Share in Volume by Application (2017-2028)
    Figure 34. Global Pelvic Congestion Syndrome Treatment Price by Application (2017-2028) & (US$/Unit)
    Figure 35. United States Pelvic Congestion Syndrome Treatment Market Share by Application in 2022 & 2028
    Figure 36. United States Pelvic Congestion Syndrome Treatment Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 37. United States Pelvic Congestion Syndrome Treatment Sales Market Share in Value by Application (2017-2028)
    Figure 38. United States Pelvic Congestion Syndrome Treatment Sales by Application (2017-2028) & (K Units)
    Figure 39. United States Pelvic Congestion Syndrome Treatment Sales Market Share in Volume by Application (2017-2028)
    Figure 40. United States Pelvic Congestion Syndrome Treatment Price by Application (2017-2028) & (US$/Unit)
    Figure 41. North America Pelvic Congestion Syndrome Treatment Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 42. North America Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 43. United States Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Canada Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Europe Pelvic Congestion Syndrome Treatment Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 46. Europe Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 47. Germany Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 48. France Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. U.K. Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Italy Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Russia Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Asia-Pacific Pelvic Congestion Syndrome Treatment Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 53. Asia-Pacific Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 54. China Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Japan Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. South Korea Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. India Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. Australia Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. China Taiwan Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Indonesia Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Thailand Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Malaysia Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Latin America Pelvic Congestion Syndrome Treatment Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 64. Latin America Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 65. Mexico Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Brazil Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Argentina Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Colombia Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Middle East & Africa Pelvic Congestion Syndrome Treatment Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 70. Middle East & Africa Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 71. Turkey Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. Saudi Arabia Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. UAE Pelvic Congestion Syndrome Treatment Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. Pelvic Congestion Syndrome Treatment Value Chain
    Figure 75. Pelvic Congestion Syndrome Treatment Production Process
    Figure 76. Channels of Distribution
    Figure 77. Distributors Profiles
    Figure 78. Bottom-up and Top-down Approaches for This Report
    Figure 79. Data Triangulation
    Figure 80. Key Executives Interviewed